A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients With Poor Prognosis Treated by Rituximab-Cyclophosphamide-Vincristine-Doxorubicin-Prednisolone Chemiotherapy (R-CHOP)

Trial Profile

A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients With Poor Prognosis Treated by Rituximab-Cyclophosphamide-Vincristine-Doxorubicin-Prednisolone Chemiotherapy (R-CHOP)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs Tazemetostat (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Mar 2018 Planned End Date changed from 1 Jan 2020 to 1 May 2023.
    • 09 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2020.
    • 11 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top